araag2/HINT huggingface dataset:
Clinical trial NCT00356135 (phase 2, status: completed)
Conditions: coronary arteriosclerosis, acute coronary syndrome
ICD codes: I25.84, I25.41, I25.42, Z98.61, Q24.5, T46.3X6S, I25.82, I24.0
Drugs: prasugrel 10 mg, clopidogrel, prasugrel placebo, prasugrel 60 mg, clopidogrel placebo
SMILES: CC(=O)OC1=CC2=C(CCN(C2)C(C(=O)C2CC2)C2=CC=CC=C2F)S1, N[C@@H](CCCNC(N)=N)C(O)=O, CC(=O)OC1=CC2=C(CCN(C2)C(C(=O)C2CC2)C2=CC=CC=C2F)S1, CC(=O)OC1=CC2=C(CCN(C2)C(C(=O)C2CC2)C2=CC=CC=C2F)S1, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Present with a recent history of an ACS event based on the disease diagnostic criteria
             between 30 and 330 days prior to enrollment, and who state that they are supposed to
             be taking daily aspirin and maintenance dose 75-mg clopidogrel.

          -  Are of a legal age (and at least 18 years of age but less than 75 years of age) and
             competent mental condition to provide written informed consent before entering the
             study.

        Exclusion Criteria:

          -  Left main coronary artery stent or left anterior descending (LAD) bifurcation stent.

          -  Have any form of coronary revascularization (percutaneous coronary intervention [PCI]
             or coronary artery bypass grafting [CABG]) planned to occur during the study (from
             signing consent through the final visit).

          -  Have undergone CABG or PCI within 30 days of entry into the study.

          -  Receiving or will receive oral anticoagulation or other antiplatelet therapy (other
             than aspirin and clopidogrel) that cannot be safely discontinued for the duration of
             the study.

          -  Receiving daily treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) that
             cannot be discontinued or are anticipated to require daily treatment with NSAIDs
             during the study.

          -  Have any of the following: history of ischemic or hemorrhagic stroke intracranial
             neoplasm, arteriovenous malformation, or aneurysm history of transient ischemic attack
             (TIA), have a body weight less than 60 kilograms (kg).
Clinical trial NCT01218126 (phase 2, status: completed)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: losmapimod, placebo
SMILES: CC1=C(C=C(C=C1F)C(=O)NC1CC1)C1=CC=C(C=N1)C(=O)NCC(C)(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  clinical history of COPD in accordance with the definition by the American Thoracic
             Society/European Respiratory Society

          -  FEV1/FVC ratio of ≤0.70

          -  FEV1 ≤ 80% of predicted normal

          -  6MWD < 350m

          -  male or female outpatients aged ≥40 years of age

          -  current or prior history of ≥10 pack-years of cigarette smoking

          -  aspartate transaminase (AST) or alanine transaminase (ALT) <2x Upper Limit Normal
             (ULN)

          -  alkaline phosphatase (alk phos), and bilirubin <1.5xULN (isolated bilirubin >1.5xULN
             is acceptable if bilirubin is fractionated and direct bilirubin <35%)

          -  QTc <450 msec* on baseline ECG. For subjects with baseline complete bundle branch
             block, the QTc must be <480msec* on baseline ECG.

        Exclusion Criteria:

          -  current diagnosis of asthma

          -  pregnant or lactating

          -  α1-antitrypsin deficiency

          -  lung resection

          -  chest X-ray (or CT scan) that reveals evidence of clinically significant abnormalities
             not believed to be due to the presence of COPD

          -  exacerbation of COPD within previous 12 weeks

          -  treatment with roflumilast within previous 2 weeks and throughout the treatment period

          -  lower respiratory tract infection that required the use of antibiotics within previous
             12 weeks

          -  long-term oxygen therapy (LTOT) or nocturnal oxygen therapy required for greater than
             12 hours a day

          -  participation in the acute phase of a Pulmonary Rehabilitation Program within 12 weeks
             or planned during the study

          -  carcinoma that has not been in complete remission for at least 5 years

          -  current or chronic history of liver disease

          -  positive Hepatitis B surface antigen or positive Hepatitis C antibody

          -  Body Mass Index (BMI) > 35

          -  known or suspected history of alcohol or drug abuse within the last 2 years
Clinical trial NCT00413660 (phase 2, status: completed)
Conditions: arthritis, rheumatoid
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: cp-690,550, cp-690,550, cp-690,550, cp-690,550, cp-690,550, cp-690,550
SMILES: [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N, [H][C@@]1(C)CCN(C[C@]1([H])N(C)C1=NC=NC2=C1C=CN2)C(=O)CC#N
Eligibility criteria:

        Inclusion Criteria:

          -  Active rheumatoid arthritis

          -  Inadequate response to stably dosed methotrexate

        Exclusion Criteria:

          -  Current therapy with any DMARD or biologic other than methotrexate
Clinical trial NCT00378209 (phase 2, status: completed)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: bortezomib, lenalidomide, dexamethasone
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of multiple myeloma based on standard diagnostic criteria or by the new
             International Myeloma Foundation 2003 Diagnostic Criteria

          -  Relapsed or relapsed and refractory disease after receiving between 1 and 3 prior
             regimens

          -  Negative serum or urine pregnancy test

          -  Age 18 years or older

          -  Karnofsky performance status of 60 or greater

        Exclusion Criteria:

          -  Grade 2 or greater peripheral neuropathy within 14 days before enrollment

          -  Renal insufficiency (serum creatinine > 2.5 mg/dL)

          -  Evidence of mucosal or internal bleeding and/or platelet refractory

          -  ANC < 1000 cells/mm3

          -  Hemoglobin < 8.0 g/dL

          -  AST or ALT greater than or equal to 2 x ULN

          -  Concomitant therapy medications that include corticosteroids

          -  Myocardial infarction within 6 months prior to enrollment or has NYHA Class III or IV
             heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or
             electrocardiographic evidence of acute ischemia or active conduction system
             abnormalities

          -  Clinically relevant active infection or serious co-morbid medical conditions

          -  Prior malignancy (within last 3 years) except for adequately treated basal cell or
             squamous cell skin cancer, in situ cervical or breast cancer, in situ prostate cancer

          -  Pregnant or breast-feeding

          -  Serious medical or psychiatric illness likely to interfere with participation in this
             clinical study.

          -  Uncontrolled diabetes mellitus

          -  Hypersensitivity to acyclovir or similar anti-viral drug

          -  POEMS syndrome

          -  Known HIV infection

          -  Known active hepatitis B or C viral infection

          -  Known intolerance to steroid therapy

          -  Subjects with primary refractory disease, defined as progression during initial
             treatment
Clinical trial NCT01054729 (phase 2, status: completed)
Conditions: hepatitis c
ICD codes: B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9
Drugs: sofosbuvir, placebo, peg, rbv
SMILES: CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Treatment-naive males and females, 18-65 years of age

          -  Genotype 1 HCV infection

          -  Negative pregnancy test for females of childbearing age

          -  Females of childbearing age and males with female partners of childbearing age must
             use two forms of contraception during treatment and following the last dose of
             ribavirin in accordance with locally approved label for ribavirin

        Exclusion Criteria:

          -  Hepatitis B or HIV infection

          -  Pregnant or breast feeding females or male partners of pregnant females

          -  Previous interferon or ribavirin-based therapy or investigational anti-HCV agent

          -  History or evidence of medical condition associated with chronic liver disease other
             than HCV
Clinical trial NCT00323804 (phase 2/phase 3, status: completed)
Conditions: hepatitis c, chronic, liver fibrosis
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4, K71.7, K70.2
Drugs: ribavirin, ribavirin-placebo
SMILES: NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Adults over 18

          -  With a hepatitis C virus infection (HCV RNA and anti-HCV antibodies in serum)

          -  Not responders to a previous antiviral treatment using the interferon plus ribavirin
             combination

          -  With a wash-out of treatment for at least 6 months

          -  With an active chronic hepatitis C and a Metavir fibrosis score ≥ 2

          -  Serum ALT levels > upper limit of the laboratory on two occasions within 6 months
             before inclusion

          -  Accepting to undergo a liver biopsy at the end of the study

          -  Negative pregnancy test for women

          -  With a social security cover

          -  Written informed consent

        Exclusion Criteria:

          -  History of hepatic complications

          -  History of transplantation

          -  History of severe seizures

          -  History of severe psychiatric disorders

          -  Drug addiction within the last 12 months

          -  Associated condition susceptible to be responsible for liver fibrosis

          -  Hepatocellular carcinoma

          -  Cardiovascular disease unstable under treatment

          -  Uncontrolled diabetes

          -  Retinopathy

          -  Thyroid disease unstable under treatment

          -  Epilepsy and/or central nervous system functional disorders

          -  Autoimmune disease

          -  Regular alcohol consumption

          -  Pregnancy, breast-feeding or absence of contraception

          -  Haemoglobin <12 g/dl

          -  platelets <50000/mm3

          -  Neutrophils < 1200/ mm3

          -  Severe hepatocellular failure (prothrombin index lower than 60%)

          -  Renal failure (creatinine clearance lower than 50 mL/Mn)

          -  Associated immunosuppressive drugs, corticosteroids, antiviral drugs (other than study
             ones)

          -  Treatment with drugs likely to have an effect on fibrosis

          -  Anticonvulsants

          -  Inability to tolerate interferon
Clinical trial NCT00006015 (phase 2, status: terminated)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: fluorouracil, leucovorin calcium, oxaliplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    lack of sufficient accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed advanced, recurrent, or metastatic colorectal adenocarcinoma

          -  Resected CNS metastases stable greater than 1 month after completion of radiotherapy
             for CNS metastases eligible

               -  No existing CNS metastases allowed

          -  Measurable disease

               -  At least 1 dimension as at least 20 mm with conventional techniques OR

               -  At least 10 mm with spiral CT scan

               -  No truly nonmeasurable lesions:

                    -  Bone lesions

                    -  Leptomeningeal disease

                    -  Lymphangitis cutis/pulmonis

                    -  Abdominal masses not confirmed and followed by imaging techniques

                    -  Cystic lesions

          -  Must have progressed on at least 1 prior, but no more than 2 prior, fluorouracil
             and/or irinotecan containing treatment regimens for metastatic colorectal cancer

          -  Must have documented HER-2/neu overexpression by immunohistochemistry staining

               -  Staining score at least 2+

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  ECOG 0-2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Granulocyte count at least 1,500/mm3

          -  Platelet count at least 100,000/mm3

        Hepatic:

          -  Bilirubin no greater than 2.0 mg/dL

          -  AST no greater than 2.5 times upper limit of normal

        Renal:

          -  Creatinine normal OR

          -  Creatinine clearance at least 60 mL/min

        Cardiovascular:

          -  No history of cardiac ischemia or congestive heart failure

          -  LVEF at least 50% by ECG or MUGA

        Other:

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No concurrent second malignancy except nonmelanoma skin cancers or carcinoma in situ
             of the cervix unless completed therapy and considered to be at less than 30% risk of
             relapse

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  See Disease Characteristics

          -  No prior platinum containing chemotherapy

          -  At least 3 weeks since prior chemotherapy and recovered

          -  No other concurrent chemotherapy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  At least 3 weeks since prior radiotherapy and recovered

        Surgery:

          -  Not specified
Clinical trial NCT00511485 (phase 2, status: completed)
Conditions: adenocarcinoma of the lung
ICD codes: D02.20, D02.21, D02.22
Drugs: vintafolide, etarfolatide
SMILES: [H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C)[C@@]1([H])[C@](O)([C@H](O)[C@]2(CC)C=CC3)C(=O)NNC(=O)OCCSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)CC[C@H](NC(=O)C1=CC=C(NCC2=CNC3=NC(N)=NC(=O)C3=N2)C=C1)C(O)=O)C(O)=O)[C@]1(C[C@@]2([H])C[N@](C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC, N[C@@H](CNC(=O)CC[C@@H](NC(=O)C1=CC=C(NCC2=CNC3=NC=NC(=O)C3=N2)C=C1)C(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Advanced, progressive, adenocarcinoma of the lung.

          -  Previously received at least 2 cytotoxic containing chemotherapeutic regimens (can
             include an epidermal growth factor receptor [EGFR] inhibitor). There is no upper limit
             to the number of prior chemotherapeutic regimens.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

          -  At least 4 weeks from prior therapy and recovered from associated acute toxicities.

          -  Radiographic evidence of measurable disease and ertafolide "positive" tumor.

          -  Adequate bone marrow reserve, hepatic, and renal function.

          -  Negative serum pregnancy test for women of childbearing potential and willingness to
             practice contraceptive methods.

        Exclusion Criteria:

          -  Serious comorbidities (as determined by the Principal Investigator).

          -  History of carcinomatous peritonitis.

          -  History of severe bowel obstruction (as determined by the Principal Investigator).

          -  Women who are pregnant or lactating.

          -  Prior radiation therapy to assessable disease, unless disease progression is confirmed
             at that site.

          -  Participants requiring palliative radiotherapy at time of study entry.

        Note: Participants with central nervous system (CNS) metastasis are eligible if a) they
        have been treated for the CNS metastasis and have been clinically stable (with regard to
        their CNS disease) for >4 weeks and b) they do not require steroids or antiseizure
        medications (i.e., for seizure control), or if the CNS metastasis has been untreated to
        date, it is not associated with a midline shift or significant edema and there is no
        clinically-evident requirement for steroids or antiseizure medication. In either situation,
        participants must be off steroids and/or antiseizure medications for at least 14 days.
Clinical trial NCT00221390 (phase 2, status: completed)
Conditions: cerebrovascular accident, hemiparesis
ICD codes: A52.05, I67.81, I67.89, I67.9, I67.841, I67.858, I67.848
Drugs: ropinirole (+ physical therapy), (vs.) placebo + physical therapy
SMILES: CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Stroke onset 4 weeks-12 months prior

          2. Stroke is radiologically confirmed as either (a) ischemic or (b) hemorrhagic

          3. Minimum age 18

          4. No significant pre-stroke disability

          5. No other stroke in previous 3 months

          6. Absence of major depression

          7. Fugl-Meyer (FM) motor score of 23-83 out of 100

          8. Functional Independence Measure (FIM) ambulation-subscore of 3 or more, and 50 foot
             walk takes longer than 15 seconds

        Exclusion Criteria:

          1. Significant daytime somnolence or any substantial decrease in alertness, language
             reception, or attention

          2. Pregnant or lactating

          3. Advanced liver, kidney, cardiac, or pulmonary disease

          4. Orthostatic hypotension

          5. Current use of ciprofloxacin, a centrally acting dopamine agonist, or a centrally
             active dopamine antagonist

          6. A terminal medical diagnosis consistent with survival < 1 year

          7. Coexistent major neurological disease

          8. Coexistent major psychiatric disease

          9. A history of significant alcohol or drug abuse in the prior 3 years

         10. A coexistent disease characterized by an abnormality of CNS dopaminergic tone

         11. Current enrollment in another investigational study related to stroke or stroke
             recovery

         12. Contraindication to ropinirole prescription
Clinical trial NCT00193245 (phase 2, status: completed)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: topotecan, docetaxel
SMILES: CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

        To be included in this study, you must meet the following criteria:

          -  Relapsed or Progressive Disease

          -  Stage IIIB (not candidate for combined modality) or IV

          -  No more than one prior chemotherapy regimen

          -  Able to perform activities of daily living without assistance

          -  Measurable disease outside of radiation port

          -  Adequate bone marrow, liver and kidney function

          -  Must understand study and sign informed consent prior to enrollment

        Exclusion Criteria:

        You cannot participate in this study if any of the following apply to you:

          -  Prior treatment with Topotecan or Docetaxel

          -  Uncontrolled brain metastases

          -  Moderate peripheral neuropathy

        Please note: There are additional inclusion/exclusion criteria. The study center will
        determine if you meet all of the criteria. If you do not qualify for the trial, study
        personnel will explain the reasons. If you do qualify, study personnel will explain the
        trial in detail and answer any questions you may have.
Clinical trial NCT00104637 (phase 2, status: completed)
Conditions: pulmonary disease, chronic obstructive, emphysema
ICD codes: J44.9, J44.1, J44.0, J43.1, J43.2, J43.8, J43.9, J98.2, J98.3, T79.7XXS
Drugs: sildenafil citrate, placebo
SMILES: CCCC1=NN(C)C2=C1NC(=NC2=O)C1=C(OCC)C=CC(=C1)S(=O)(=O)N1CCN(C)CC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical diagnosis of chronic obstructive pulmonary disease (COPD) or emphysema

          -  FEV1/FVC ratio < 70%

          -  FEV1 < 80%

          -  Stable medication regimen

        Exclusion Criteria:

          -  COPD exacerbation or hospitalization in the past 3 months

          -  Heart disease

          -  Contraindication to sildenafil

          -  Unrelated lung disease

          -  Inability to walk or pedal on a stationary bike

          -  Pregnancy or breast-feeding

          -  Pulmonary hypertension at rest
Clinical trial NCT00297830 (phase 2/phase 3, status: completed)
Conditions: heart transplantation, liver transplantation, bone resorption
ICD codes: M31.11, Z52.6, K71.8, K71.7, A06.4, C22.0, C22.3, K70.0
Drugs: zoledronic acid, alendronate
SMILES: OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O, COC1=CC2=C(C=C1)C=C(C=C2)[C@H](C)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  A man or woman, aged 20 to 70, of any race who has had a heart or liver transplant

        Exclusion Criteria:

          -  hyperparathyroidism

          -  Paget's disease

          -  hyperthyroidism

          -  cancer

          -  severe kidney disease,

          -  intestinal disease

          -  active peptic ulcer disease

          -  current or past treatment for osteoporosis

          -  pregnancy or lactation

          -  severe oral/dental disease